Navigation Links
InterMune to Release Second Quarter Financial Results on August 4
Date:7/28/2011

BRISBANE, Calif., July 28, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that it will release its second quarter 2011 financial results on Thursday, August 4, 2011. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day to discuss business highlights and financial results for the second quarter and first six months of 2011.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 80082950.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80082950.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
2. InterMune to Webcast 2011 Analyst Day Presentations
3. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
4. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
5. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
6. InterMune to Release First Quarter Financial Results on April 28
7. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
9. InterMune to Release Third Quarter Financial Results on October 28
10. InterMune Sells Danoprevir Rights to Roche for $175 Million
11. InterMune to Present at 2010 Citi Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 that ... menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM ... screening for blood donors under an Investigational New Drug (IND) study protocol. , ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... ... 25, 2017 , ... Franz Inc ., an early ... and market leader for Semantic Graph Database technology, today announced ... most effective system for developing and deploying applications to solve the challenges developers ...
(Date:4/25/2017)... ... 2017 , ... Dr. Robert G. Schwartz, the principal of ... that acclaimed physiatrist Matthew Terzella, MD, has joined the practice as a partner, ... completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert Wood Johnson and ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):